Clinical, Histopathological, and Molecular Characteristics of Papillary Thyroid Microcarcinoma

Lim, Dong-Jun; Baek, Kwang‐Hyun; Lee, Youn-Soo; Park, Woo-Chan; Kim, Meekyoung; Kang, Moo Il; Jeon, Hoon; Lee, Jongmin; Yun-Cha, Bong; Lee, Kwang-Woo; Son, Ho‐Young; Kang, Suk‐Ku

doi:10.1089/thy.2007.0001

Cited by 69 publications

(64 citation statements)

References 40 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In agreement with this, EGFR and VEGFR2 overexpression has been shown to be closely correlated to advanced tumor stage, metastasis, and poor clinical outcome in several human cancers. With respect to thyroid carcinomas, EGFR overexpression has been detected in most anaplastic tumors (Schiff et al 2004, Wiseman et al 2007, Elliott et al 2008 and to a much lower extent in PTCs (Schiff et al 2004, Murakawa et al 2005, Mitsiades et al 2006, Lim et al 2007, Elliott et al 2008. In PTC, EGFR expression has been associated to poor prognosis (Akslen & Varhaug 1995, Chen et al 1999, although not always (Lim et al 2007), and recent studies have suggested that EGFR inhibitors might be active against anaplastic thyroid carcinomas (Lopez et al 2008).…”

Section: Discussionmentioning

confidence: 99%

“…With respect to thyroid carcinomas, EGFR overexpression has been detected in most anaplastic tumors (Schiff et al 2004, Wiseman et al 2007, Elliott et al 2008 and to a much lower extent in PTCs (Schiff et al 2004, Murakawa et al 2005, Mitsiades et al 2006, Lim et al 2007, Elliott et al 2008. In PTC, EGFR expression has been associated to poor prognosis (Akslen & Varhaug 1995, Chen et al 1999, although not always (Lim et al 2007), and recent studies have suggested that EGFR inhibitors might be active against anaplastic thyroid carcinomas (Lopez et al 2008). In thyroid neoplasias, overexpression of VEGF and platelet-derived growth factor receptor have been described, and disruption of VEGF signaling has been shown to inhibit thyroid cancer cell growth in vitro and in vivo (Tuttle et al 2002, Turner et al 2003, Lin & Chao 2005, Vieira et al 2005.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis

Rodríguez‐Antona

Pallarés²,

Montero‐Conde³

et al. 2010

Endocrine-Related Cancer

120

View full text Add to dashboard Cite

Therapeutic options for patients with metastatic medullary thyroid carcinoma (MTC) are limited due to lack of effective treatments. Thus, there is a need to thoroughly characterize the pathways of molecular pathogenesis and to identify potential targets for therapy in MTC. Since epidermal growth factor receptor (EGFR) seems to play a crucial role for RET activation, a key feature of MTCs, and several promising EGFR/vascular endothelial growth factor receptor 2 (VEGFR2)-targeted drugs have been developed, the present study was designed to investigate whether these proteins are altered in MTCs. We used a well-characterized series of 153 MTCs to evaluate EGFR activation by sequencing and FISH analysis, and to perform EGFR and VEGFR2 immunohistochemistry. EGFR tyrosine kinase domain mutations were not a feature of MTCs; however, EGFR polysomy and a strong EGFR expression were detected in 15 and 13% of the tumors respectively. Interestingly, EGFR was significantly overexpressed in metastases compared with primary tumors (35 vs 9%, PZ0.002). We also studied whether specific RET mutations were associated with EGFR status, and found a decrease in EGFR polysomies (PZ0.006) and a tendency towards lower EGFR expression for the most aggressive RET mutations (918, 883). Concerning VEGFR2, metastasis showed a higher expression than primary tumors (PZ2.8!10 K8 ). In this first study investigating the relationship between EGFR, RET, and VEGFR2 in a large MTC series, we found an activation of EGFR and VEGFR2 in metastasis, using both independent and matched primary/metastasis samples. This suggests that some MTC patients may benefit from existing anti-EGFR/VEFGR2 therapies, although additional preclinical and clinical evidence is needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis

Rodríguez‐Antona

Pallarés²,

Montero‐Conde³

et al. 2010

Endocrine-Related Cancer

120

View full text Add to dashboard Cite

show abstract

“…Recently, it has been reported that the absence of epidermal growth factor receptor expression was positively correlated with the presence of lymph node metastases (23). Some studies evaluated whether the expression of cyclin D1 and galectin-3 in PTMC could be a marker of lymph node metastases (145)(146)(147).…”

Section: Risk Factors For the Presence Of Lymph Node Metastases At DImentioning

confidence: 99%

Thyroid papillary microcarcinoma: a descriptive and meta-analysis study

Roti

Uberti

Bondanelli

et al. 2008

European Journal of Endocrinology

287

229

View full text Add to dashboard Cite

The authors review anatomical, clinical characteristics and prevalence of thyroid microcarcinoma. Diagnostic procedures and risk factors of aggressiveness at diagnosis and during follow-up are also covered. The possible clinical, pathologic and therapeutic risk factors are analyzed by meta-analysis study. Treatment procedures by different authors and guidelines suggested by societies are reported.European Journal of Endocrinology 159 659-673

show abstract

“…Assessing the MIB-1 in evaluating proliferative activity and predicting the aggressiveness of the tumor types is very useful (Nakayama et al, 2007;Pesutic-Pisac et al, 2008;Pujani et al, 2010;Ranjbari and Rahim, 2013). In spite of the fact the index of the Ki-67 cell marker (ki-67 labeling index = LI) for the diagnosis of thyroid neoplasms has been studied but the relationship between the papillary thyroid carcinoma and the ki-67 LI and the biological behavior is not well understood (Lim et al, 2007;Pujani et al, 2010). Some studies conducted on patients with the PTMC with the high ki-67 LI levels, obviously demonstrated that they had the lower disease-free survival and higher rates of the disease recurrence, compared with the PTMC and PTC (macro carcinoma) with Low Ki-67 LI (Hay et al, 1992;Siironen et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

Correlation of KI-67/MIB-1 in the Papillary Macro and Micro-carcinomas of the Thyroid Gland with the Prognosis of the Patients

Saki¹,

Bonab²,

Ranjbari³

et al. 2014

Asian J. of Cell Biology

View full text Add to dashboard Cite

The Papillary Thyroid Carcinoma (PTC) has the ability to show an aggressive clinical course and regional lymph node metastasis. This study was conducted to assess the Ki-67 labeling index (Ki-67.LI) as a prognostic factor to identify a high risk group of the macro-and micro PTC to elucidate this issue. All 98 patients with the thyroid mass that underwent thyroidectomy enrolled in this study, then people were divided into two equal groups of case (PTC) and control (Benign thyroid lesions). We evaluated the ki-67.LI in their primary lesions and revealed its relationship with the various features of prognostic variables. The patients, who were followed-up during 24 months and recurrence and distant metastasis was proved. The ki-67.LI had statistically significant correlation with the tumor size (p = 0.003), the vascular invasion and regional lymphatic involvement (p<0.001). An extra thyroid tissue invasion and extensive tumor necrosis were detected, with the high LI (p<0.001). The tumor multifocality was correlated with the LI>2.8% (p = 0.004). Among the remaining with the LI >2.8%, one patient with the Papillary Thyroid Micro Carcinoma (PTMC) and three patients with the Papillary Thyroid Carcinoma (PTC) were with the recurrence after the surgery. The ki-67.LI revealed a close correlation with the vascular-lymphatic invasion, the nodal metastasis, extra-thyroid extension and an extension of the necrosis and the infiltrative tumor borders. An evaluation of the ki-67 could be helpful to detect the high risk patient especially for the patient with papillary thyroid micro carcinoma.

show abstract

Clinical, Histopathological, and Molecular Characteristics of Papillary Thyroid Microcarcinoma

Cited by 69 publications

References 40 publications

Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis

Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis

Thyroid papillary microcarcinoma: a descriptive and meta-analysis study

Correlation of KI-67/MIB-1 in the Papillary Macro and Micro-carcinomas of the Thyroid Gland with the Prognosis of the Patients

Contact Info

Product

Resources

About